Zylox-Tonbridge Medical repurchases 17,500 H shares for HK$0.34 million, bringing total buy-backs to 3.25 million under 2026 mandate

Bulletin Express

Jul 06

Zylox-Tonbridge Medical Technology Co., Ltd. reported that it bought back 17,500 H shares on 6 July 2026 via on-market transactions at HK$19.52 per share, spending HK$0.34 million in total.

The repurchase reduced the company’s outstanding issued shares (excluding treasury shares) from 323.98 million to 323.96 million, a marginal contraction of 0.0053%. The acquired stock has been retained as treasury shares, lifting the treasury share balance to 12.39 million, while the company’s total issued share capital remains unchanged at 336.35 million.

Since receiving shareholder approval on 13 May 2026 for a mandate covering up to 32.72 million shares, Zylox-Tonbridge Medical has repurchased 3.25 million shares, representing 9.93% of the authorised limit and 0.97% of the issued share base at mandate date.

Under Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 5 August 2026 following this latest buy-back.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143015545"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143015545\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143015545?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143015545","market":"hk","top_or_hot":-1,"title":"Zylox-Tonbridge Medical repurchases 17,500 H shares for HK$0.34 million, bringing total buy-backs to 3.25 million under 2026 mandate","media":"Bulletin Express","content":"<p>Zylox-Tonbridge Medical Technology Co., Ltd. reported that it bought back 17,500 H shares on 6 July 2026 via on-market transactions at HK$19.52 per share, spending HK$0.34 million in total.</p>\n<p>The repurchase reduced the company’s outstanding issued shares (excluding treasury shares) from 323.98 million to 323.96 million, a marginal contraction of 0.0053%. The acquired stock has been retained as treasury shares, lifting the treasury share balance to 12.39 million, while the company’s total issued share capital remains unchanged at 336.35 million.</p>\n<p>Since receiving shareholder approval on 13 May 2026 for a mandate covering up to 32.72 million shares, Zylox-Tonbridge Medical has repurchased 3.25 million shares, representing 9.93% of the authorised limit and 0.97% of the issued share base at mandate date.</p>\n<p>Under Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 5 August 2026 following this latest buy-back.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zylox-Tonbridge Medical repurchases 17,500 H shares for HK$0.34 million, bringing total buy-backs to 3.25 million under 2026 mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZylox-Tonbridge Medical repurchases 17,500 H shares for HK$0.34 million, bringing total buy-backs to 3.25 million under 2026 mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-06 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zylox-Tonbridge Medical Technology Co., Ltd. reported that it bought back 17,500 H shares on 6 July 2026 via on-market transactions at HK$19.52 per share, spending HK$0.34 million in total.</p>\n<p>The repurchase reduced the company’s outstanding issued shares (excluding treasury shares) from 323.98 million to 323.96 million, a marginal contraction of 0.0053%. The acquired stock has been retained as treasury shares, lifting the treasury share balance to 12.39 million, while the company’s total issued share capital remains unchanged at 336.35 million.</p>\n<p>Since receiving shareholder approval on 13 May 2026 for a mandate covering up to 32.72 million shares, Zylox-Tonbridge Medical has repurchased 3.25 million shares, representing 9.93% of the authorised limit and 0.97% of the issued share base at mandate date.</p>\n<p>Under Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 5 August 2026 following this latest buy-back.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02190","symbol_name":"归创通桥","start_time":0,"source_url":"","article_id":"1143015545","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143015545","pubTimestamp":1783336038,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Zylox-Tonbridge Medical Technology Co., Ltd. reported that it bought back 17,500 H shares on 6 July 2026 via on-market transactions at HK$19.52 per share, spending HK$0.34 million in total. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02190":"归创通桥"},"translate_title":"归乐通桥医疗以34万港元回购17,500股H股，根据2026年授权回购总额达到325万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02190":1},"content_text":"Zylox-Tonbridge Medical Technology Co., Ltd. reported that it bought back 17,500 H shares on 6 July 2026 via on-market transactions at HK$19.52 per share, spending HK$0.34 million in total.\nThe repurchase reduced the company’s outstanding issued shares (excluding treasury shares) from 323.98 million to 323.96 million, a marginal contraction of 0.0053%. The acquired stock has been retained as treasury shares, lifting the treasury share balance to 12.39 million, while the company’s total issued share capital remains unchanged at 336.35 million.\nSince receiving shareholder approval on 13 May 2026 for a mandate covering up to 32.72 million shares, Zylox-Tonbridge Medical has repurchased 3.25 million shares, representing 9.93% of the authorised limit and 0.97% of the issued share base at mandate date.\nUnder Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 5 August 2026 following this latest buy-back.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}